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Novelty and Impact:  
Whilst squamous carcinoma of the cervix has been on the decline in countries with 
organised screening, adenocarcinoma has become more common. Our results suggest that 
cytology screening is inefficient at preventing adenocarcinoma, however it does detect early-
stage invasive adenocarcinoma and thus substantially prevents stage2 and worse 
adenocarcinomas. Stage 1A adenosquamous carcinoma of the cervix is very rare, but 
screening is preventing a substantial proportion of stage 1B or worse adenosquamous 
cervical cancer.
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Whilst the incidence of squamous carcinoma of the cervix has declined in countries with 
organised screening, adenocarcinoma has become more common. Cervical screening by 
cytology often fails to prevent adenocarcinoma. Using prospectively recorded cervical 
screening data in England and Wales we conducted a population based case-control study 
to examine whether cervical screening leads to early diagnosis and down staging of 
adenocarcinoma. Conditional logistic regression modelling was carried out to provide odds 
ratios (OR) and 95% confidence intervals on 12,418 women with cervical cancer diagnosed 
between ages 30-69 and 24,453 age-matched controls. Of women with adenocarcinoma of 
the cervix, 44.3% were up to date with screening and 14.6% were non-attenders. The overall 
OR comparing women up to date with screening with non-attenders was 0.46(95%CI:0.39-
0.55) for adenocarcinoma. The odds were significantly decreased (OR: 0.22, 95%CI:0.15-
0.33) in up to date women with stage 2 or worse adenocarcinoma, but not for women with 
stage1A adenocarcinoma 0.71(95%CI:0.46-1.09). The odds of stage 1A adenocarcinoma 
was double among lapsed attenders (OR: 2.35, 95%CI:1.52-3.62) compared with non-
attenders. Relative to women with no negative cytology within seven years of diagnosis, 
women with stage1A adenocarcinoma were very unlikely to be detected within 3 years of a 
negative cytology test (OR: 0.08, 95%CI:0.05-0.13), however the odds doubled 3-5 years 
after a negative test (OR: 2.30, 95%CI:1.67-3.18). ORs associated with up to date screening 
were smaller for squamous and adenosquamous cervical carcinoma. Although cytology 
screening is inefficient at preventing adenocarcinomas, invasive adenocarcinomas are 
detected earlier than they would be in the absence of screening, substantially preventing 
stage 2 and worse adenocarcinomas.  
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The distribution of the main cervical cancer morphological types has changed considerably 
in countries with organised screening programmes.1, 2 Although squamous carcinoma 
continues to be the most frequent morphological type worldwide, increases in the incidence 
of adenocarcinoma (particularly among younger women) have been observed in several 
countries such as the United States3-5, Italy6 and Sweden.7 In England the proportion of 
cervical cancers that are squamous carcinoma decreased from 82.6% in 1989 to 70.4% in 
2009.8 Conversely the proportion that are adenocarcinoma increased from 13.2% in 1989 to 
22.1% in 2009, while the proportion that are adenosquamous carcinoma has remained fairly 
constant (2.3% vs. 3.6%).8 
The first analysis providing evidence of the effectiveness of screening in the prevention of 
cervical cancer only considered squamous carcinoma.9  There has since emerged a growing 
body of literature suggesting that screening is less effective against adenocarcinoma than 
squamous carcinoma of the cervix.7, 10-12 The natural history of adenocarcinoma of the cervix 
differs from that of squamous carcinoma, with glandular precancerous lesions 
(adenocarcinoma in situ) thought to be harder to sample than squamous precancerous 
lesions (cervical intraepithelial neoplasia), as they typically develop within the endocervical 
canal, which often fails to be sampled by cytology.13 As a result, adenocarcinoma is often 
diagnosed at more advanced stages and has a worse prognosis than squamous 
carcinoma.14 
Few authors have considered the effectiveness of screening against adenosquamous 
carcinoma, but it appears to be similar to that of squamous carcinoma.15 
We hypothesise that cervical screening by cytology often fails to prevent adenocarcinoma of 
the cervix, but has the benefit of leading to early diagnosis and down-staging. We update 
previous research15, with data on an additional 9,472 women with cervical cancer, to explore 
the effect of screening on the likelihood of developing adenocarcinoma of the cervix in 
comparison to squamous carcinoma and adenosquamous carcinoma of the cervix. 
Materials and Methods 
Study Population 
Currently the NHS Cervical Screening Programme in England invites women aged 25-49 for 
three yearly screens, and women aged 50-64 for five yearly screens. In Wales during the 
study period women aged 25-64 were invited for three yearly screens. The programme is 
organised through a national call/recall system where those who test negative (and those 
who do not attend) are invited again after 3 or 5 years depending on age (routine recall 
action code), those with low-grade abnormalities are triaged using HPV testing and those 
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with high grade abnormalities are referred to colposcopy (suspended from recall). Prior to 
2012, women with low-grade abnormalities were invited for re-screening at 6-12 months 
(early recall action code).  
Since April 2007 data collection in England and Wales has been nationally audited and it is 
estimated that 96% of cervical cancers in women aged 30-69 are included.16 Data on 
screening histories were abstracted from routinely recorded cervical cytology records held 
on the Cervical Screening Call/Recall System, and were therefore not subject to recall bias. 
These records include all NHS (and many private provider) smears taken in the UK since 
1988. After local NHS staff linked screening data to cases and controls, the data were 
anonymised locally before being transferred for cleaning and analysis. Guidelines on the 
collection of data for this audit and details of the design have been published previously.17-19 
In our study, cases were women aged 30 to 69 when they were diagnosed with cervical 
cancer (ICD-10 C53) in England (between January 1990 and July 2014) and Wales 
(between January 1999 and May 2013) (data were extracted from the database locked in 
July 2014),  registered with an NHS general practitioner (GP). Eligible controls for each case 
were all other women registered with an NHS GP at the time of a case’s diagnosis. Controls 
were assigned the date of diagnosis of their matched case. Two controls were individually 
matched within a year of birth to each case and on place of residence: one control had the 
same general practice as the case, and a second control had a different general practice but 
within the same administrative area. If only one control could be identified, the second was 
selected from a different GP to avoid possible overmatching if screening uptake was 
associated with the GP’s enthusiasm for cervical screening. Controls were randomly 
selected (using a computer program) from women who satisfied the matching criteria. Data 
were collected on all selected controls, to eliminate possible participation bias. Stage was 
recorded as per the FIGO (Fédération Internationale de Gynécologie et d’Obstétrique) 
stages. 
Classification of screening exposure  
To create a screening classification, women were defined as (i) never having been 
screened, (ii) up to date with their screening, or (iii) having been screened in the past, but 
lapsed at the time of diagnosis. A woman was considered to be lapsed if the last smear had 
a routine action code (i.e. they were invited to return for screening at the normal interval, 3 or 
5 years depending on age) dated over 3.5 (age <50) or 5.5 (age ≥50) years before 
diagnosis, had an early recall action code dated more than 1.25 years before diagnosis, or 
had a suspend action code dated over 6 months before diagnosis. To be considered as “up 
to date with screening” in this paper, women needed to have attended screening in the last 
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3.5 (or 5.5) years depending on age. Women aged 66 and over needed to have been 
screened between the ages of 60-64 because screening is not offered beyond age 64. 
The time since last negative screen was defined as the time between the last operationally 
negative smear and the date of diagnosis. An operationally negative smear has both a 
negative result and a routine action code, implying that the woman is not being followed-up 
for a previous abnormal result. Women with no negative smears prior to diagnosis were 
combined with women whose last negative smear was >7 years before diagnosis.  
Statistical analyses 
Conditional logistic regression modelling was carried out to provide odds ratios and 95% 
confidence intervals.   
To explore whether the differences in the effect of screening were due to differences in the 
age distributions for each morphological type of cancer, we carried out an (internally) age-
standardised analysis of squamous carcinomas as follows: for each woman with 
adenocarcinoma we randomly selected two age matched (within 24 months of age at 
diagnosis) women with squamous carcinoma. Analysis was then restricted to those age-
matched squamous cases and their controls, thus giving the squamous carcinoma cases the 
same age distribution as the adenocarcinomas.  
Women were excluded if the morphological type of cancer was recorded as other (N=330) or 
unknown morphology in the dataset (N=1347).  
Analyses were carried out in Stata version 12.20  
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The analysis included 12,418 women with cervical cancer diagnosed aged 30-69 and 24,453 
controls. Of the cancers in this study, 9,472 (76.3%) have not been analysed before; the 
remaining 23.7% were included in a previous publication.15 The majority of the cancers were 
squamous carcinoma (74.7%), followed by adenocarcinoma (21.9%) and adenosquamous 
carcinoma (3.4%). Among those with known stage, a large proportion of squamous 
carcinoma were diagnosed as stage 1A cancer (38.8%) compared with adenocarcinoma 
(24.2%) and adenosquamous carcinoma (6.9%) (Table 1). However, 53.4% of 
adenocarcinoma (and 55.6% of adenosquamous) cancers were diagnosed as stage 1B 
compared with 31.2% of squamous. Over a third of adenosquamous carcinoma was 
diagnosed as stage 2 or worse (37.5%), compared with less than a third of squamous and 
adenocarcinoma (30% and 22.4% respectively). Of particular note is the very low proportion 
(7%) of adenosquamous carcinoma that were diagnosed at stage 1A compared with 39% of 
squamous cases and 24% of adenocarcinomas.  
Of women with adenocarcinoma of the cervix, 44.3% were up to date with their screening, 
and the proportion of women with adenocarcinoma who had never been screened (14.6%) 
was lower than the proportion observed for the two other histological types (28.3% for 
squamous and 26.2% for adenosquamous) (Table 1). The odds ratio of developing stage 1A 
adenocarcinoma was not significantly lower in women with up to date screening compared 
with never screened women (OR 0.71, 95% CI 0.46-1.09) (Table 2).The odds ratio was 
double among women with lapsed screening compared with those never screened (OR 2.35, 
95% CI 1.52-3.62). Conversely, the odds ratio of developing stage 1B (OR 0.54, 95% CI 
0.41-0.71) or stage 2 or worse (OR 0.22, 95% CI 0.15-0.33) adenocarcinoma of the cervix 
was significantly decreased in women with up to date screening compared with those never 
screened. Although the odds ratio of developing stage 1A squamous carcinoma was 
increased in lapsed attenders (OR 1.31, 95% CI 1.13-1.52) compared with never screened 
women, it was significantly decreased in both up to date and lapsed attenders with stage 2 
or worse cancer (Table 2). The odds of a diagnosis of adenosquamous cancer, both overall 
and by stage, were very similar to the odds observed for squamous carcinoma, while those 
for adenocarcinoma were always higher. 
To ensure that the differences in the effect of screening were not due to differences in the 
age distributions for each morphological type of cancer, we estimated odds ratios for a 
restricted set of women with squamous cancers with the same age distribution as women 
with adenocarcinoma (Table 2). These age-standardised estimates were similar to those that 
included all squamous cancers, showing that the difference in results between squamous 
carcinoma and adenocarcinoma was not a result of differences in age distribution. 
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Compared with never screened women, adenocarcinoma stage 1A was very unlikely to be 
detected in women within 3 years of a negative cytology test (OR 0.08, 95% CI 0.05-0.13), 
however the odds of stage 1A adenocarcinoma was double at 3-5 years after a negative test 
(OR 2.30, 95% CI 1.67-3.18) (Table 3). Similarly, the risk of developing stage 1B 
adenocarcinoma within 3 years of a negative cytology test was small (OR 0.19, 95% CI 0.15-
0.23) compared with never screened women, but an increased risk was observed for women 
whose last negative screen was 3-5 years earlier (OR 1.32, 95% CI 1.07-1.62). The odds of 
developing squamous carcinoma remained low up to 7 years following a negative test. 
Again, the magnitude of the effect observed for adenosquamous cancer was similar to that 
for squamous cancer, while that for adenocarcinoma was always higher. 
Discussion 
We have shown for the first time that screening is associated with a decreased odds of 
advanced-stage adenocarcinoma of the cervix and an increased odds of early stage 
adenocarcinoma. Despite over 40% of women diagnosed with adenocarcinoma of the cervix 
having an up to date screening history, no reduction in the odds of developing stage 1A 
adenocarcinoma was observed. However, stage 1A adenocarcinoma was very unlikely to be 
diagnosed within 3 years of a negative screen, and a significant reduction in the odds of 
adenocarcinoma was observed with up to date screening for cancers stage 1B or worse. 
This suggests that, although cytology may lack sensitivity for the detection of precursors of 
adenocarcinoma, it is sensitive at detecting early stage adenocarcinoma. The odds of 
developing stage 1B or worse cancers were reduced in women with up to date screening. 
The effect of screening on adenosquamous carcinoma was similar to that observed for 
squamous carcinoma, but the magnitude of the effect was smaller.  
A strength of the present study is its use of routinely recorded data on screening, linked to 
cancer diagnosis in a case–control design that avoids selection and recall bias. To our 
knowledge, this is the largest study assessing the impact of screening on adenocarcinomas 
of the cervix. Our study includes 2,717 women (of whom 2,216 have known FIGO stage) 
diagnosed with adenocarcinoma, compared with a combined total of 1,177 women from 
seven other studies.7, 10-12, 21-23 
It is well documented that screening is less effective in young women24, and there was 
concern that the difference in the effect of screening between morphological types could be 
due to a difference in the age distribution of women with different histological types of 
cervical cancer.10 We found that, after internal age-standardisation, the odds ratio of 
developing squamous cervical cancer did not significantly change.  
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This is an observational study, so we cannot prove that the association between screening 
and a reduction in the risk of developing cervical cancer is causal. However, there is 
increasing evidence9, including a randomised controlled trial25, suggesting the association is 
indeed causal. We have no information on risk factors for cervical cancer (such as smoking 
and sexual history), however the likelihood that the difference in the odds ratios is due to 
confounding seems small, because the known risk factors for squamous and 
adenocarcinoma of the cervix are similar.26  
Our results are in line with the rest of the literature. Several authors have found cytology 
screening to be less effective in preventing adenocarcinoma than squamous carcinoma of 
the cervix.10, 11 Only one small study, including 17 adenocarcinomas, found no difference in 
the effect of screening between morphological types.21 Mitchell et al12 showed a reduction in 
the risk of adenocarcinoma within a year of a negative test, and Nieminen et al27 showed 
that mortality among women with adenocarcinoma of the cervix decreased, while incidence 
remained unchanged, both suggesting but not directly showing that screening is down 
staging adenocarcinoma. More directly, Pettersson et al7 showed a five-fold increase in the 
proportion of cancers being diagnosed as adenocarcinoma, particularly among young 
women, but also showed that they are being diagnosed at an earlier stage in the latest 
screening cohorts. Further, Andrae et al28 showed that survival from adenocarcinoma of the 
cervix (regardless of the stage) was better among those who had been screen-detected 
compared with those with symptomatic presentation. However, no difference was observed 
(after adjusting for stage) between those who were up to date with their screening and those 
who had not been screened or were lapsed. 
Given the rarity of diagnoses of adenocarcinoma in situ or high-grade cervical glandular 
intraepithelial neoplasia , it is not surprising that the majority of adenocarcinomas are not 
prevented by screening. However, there is evidence of a positive association between 
screening coverage and the proportion of adenocarcinoma diagnosed.13 The low risk of 
stage 2 or worse adenocarcinoma within three years of a negative cervical cytology, and at 
3-7 years after a previous negative, suggests that cytology is good at detecting early stage 
invasive adenocarcinoma, and this is primarily leading to the reduction in advanced 
adenocarcinoma associated with regular screening. 
The results suggest that screening is inefficient at preventing adenocarcinoma of the cervix, 
but is good at detecting stage 1A adenocarcinoma. In the absence of screening, 
adenocarcinoma typically will not be diagnosed until stage 1B or worse. Thus, stage 1A 
adenocarcinoma is most common in women screened irregularly, in whom there is sufficient 
time for a 1A cancer to have developed since their last screen, but insufficient time for it to 
have progressed to stage 1B or worse 
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The fact that screening does have an effect on stage 1B or worse adenosquamous 
carcinoma suggests that the squamous component must be stronger and/or appear earlier in 
the carcinogenic process, allowing its detection through screening. There is only sparse 
literature on the epidemiology of cervical adenosquamous carcinoma, but based on the mix 
of HPV types found in these cancers (HPV-16 (39%), -18 (32%), -45 (12%), -31 (2%) and -
33 (3%)29) it could be assumed that they have more in common with adenocarcinoma than 
with squamous carcinoma. This is at odds with the findings here, unless adenosquamous 
cancers develop primarily from HPV18 positive squamous carcinoma. 
It has been suggested that in cytology the lack of sensitivity to adenocarcinoma may be due 
to these cancers developing in the endocervical canal, making sampling of abnormal cells 
difficult. The introduction of primary HPV testing may help tilt the balance in favour of 
adenocarcinoma. A pooled analysis from the HPV primary screening trials examining 
cervical cancer suggests that HPV testing will have a bigger impact on adenocarcinoma (OR 
0.31, 95% CI 0.14-0.69) than on squamous carcinoma (OR 0.78, 95%CI 0.49-1.25) 
compared with cytology.30 However, it is unclear whether HPV testing is more or less 
sensitive than cytology in detecting early stage invasive adenocarcinoma. 
Five high risk HPV types are found in 92% of adenocarcinomas (HPV-16 (41.6%), -18 
(38.7%), -45 (7.0%), -31 (2.2%) and -33 (2.1%)).13, 29 HPV vaccination will provide the best 
prevention strategy against adenocarcinomas of the cervix. Both available vaccines protect 
against HPV types 16 and 18, and the bivalent vaccine (Cervarix) has strong cross 
protection against types 45, 31 and 33.31 Nevertheless, there is some evidence to suggest 
that even after testing with multiple HPV assays, some cancers remain HPV negative, and 
these are more likely to be adenocarcinomas.32 
Conclusions 
Cytology based screening has been less effective in preventing adenocarcinoma of the 
cervix than in preventing squamous carcinoma. However, screening detects 
adenocarcinoma earlier than diagnosis in the absence of screening, leading to a down 
staging of disease. In the future, a combination of HPV vaccination, HPV testing and new 
technologies will result in a considerable decrease in the burden of adenocarcinoma of the 
cervix. 
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Table 1. Main characteristics of women included in the study. 
  Squamous  Adenocarcinoma Adenosquamous 
  N % N % N % 
FIGO Stage 
 1A 3051 38.8 537 24.2 24 6.9 
1B 2449 31.2 1,183 53.4 194 55.6 
2+ 2,355 30.0 496 22.4 131 37.5 
Not recorded 1,419 - 501 - 78 - 
Age Group 
30-39 3640 39.2 1008 37.1 148 34.7 
40-49 2621 28.3 903 33.2 125 29.3 
50-69 3013 32.5 806 29.7 154 36.1 
Screening history 
Screened up to date 2335 25.2 1,203 44.3 128 30.0 
Screened lapsed 4310 46.5 1118 41.1 187 43.8 
Never screened 2629 28.3 396 14.6 112 26.2 
Total 9,274 100 2,717 100 427 100 
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Table 2. Odds ratios (OR) and 95% confidence intervals (CI) of developing cervical cancer by morphological type, 
screening classification and stage. 
  Age 30-69 Age standardised 
squamous cancer* 
All FIGO stages 
Squamous Adenocarcinoma Adenosquamous 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Screened up to date 0.14 (0.12-0.15) 0.46 (0.39-0.55) 0.16 (0.11-0.24) 0.13 (0.12-0.15) 
Screened lapsed 0.76 (0.70-0.83) 1.28 (1.07-1.53) 0.70 (0.47-1.04) 0.73 (0.66-0.82) 
Never 1 1 1 1 
Stage 1A   
Screened up to date 0.27 (0.23-0.31) 0.71 (0.46-1.09) 0.27 (0.04-1.77) 0.25 (0.20-0.30) 
Screened lapsed 1.31 (1.13-1.52) 2.35 (1.52-3.62) 1.12 (0.16-7.90) 1.20 (0.99-1.46) 
Never 1 1 1 
 
Stage 1B   
 
Screened up to date 0.17 (0.14-0.20) 0.54 (0.41-0.71) 0.24 (0.13-0.44) 0.17 (0.13-0.21) 
Screened lapsed 0.93 (0.78-1.10) 1.43 (1.07-1.91) 0.81 (0.43-1.53) 0.87 (0.69-1.09) 
Never 1 1 1 1 
 
Stage 2+   
 
Screened up to date 0.05 (0.04-0.06) 0.22 (0.15-0.33) 0.07 (0.03-0.15) 0.07 (0.06-0.09) 
Screened lapsed 0.40 (0.33-0.47) 0.59 (0.38-0.90) 0.58 (0.28-1.18) 0.51 (0.43-0.61) 
Never 1   1   1       
*Two squamous cancers were selected matching on age to each adenocarcinoma, so as to give the squamous cancers 
the same age distribution as the adenocarcinomas. 
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Table 3. Odds ratio (OR) and 95% confidence intervals (CI) of developing cervical 
cancer by morphology, time since last negative test, and stage.  
  Squamous  Adenocarcinoma Adenosquamous 
  OR 95% CI OR 95% CI OR 95% CI 
Stage 1A 
<3 yrs 0.02 (0.02-0.03) 0.08 (0.05-0.13) 0.25 (0.00-0.29) 
3-5 yrs 0.88 (0.77-1.01) 2.30 (1.67-3.18) 0.28 (0.05-1.66) 
5-7 yrs 1.09 (0.91-1.30) 2.76 (1.74-4.37) 0.55 (0.11-2.74) 
>7yrs or never 1 1 1* 
Stage 1B 
<3 yrs 0.05 (0.04-0.06) 0.19 (0.15-0.23) 0.09 (0.05-0.17) 
3-5 yrs 0.51 (0.43-0.59) 1.32 (1.07-1.62) 0.78 (0.47-1.29) 
5-7 yrs 0.55 (0.45-0.68) 1.23 (0.93-1.62) 1.45 (0.69-3.04) 
>7yrs or never 1 1 1 
Stage 2+ 
<3 yrs 0.04 (0.03-0.05) 0.17 (0.13-0.24) 0.07 (0.03-0.14) 
3-5 yrs 0.14 (0.11-0.17) 0.43 (0.31-0.60) 0.09 (0.04-0.23) 
5-7 yrs 0.20 (0.15-0.25) 0.52 (0.33-0.80) 0.34 (0.15-0.81) 
>7yrs or never 1   1   1   
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